630P Apalutamide for non-metastatic castration resistant prostate cancer (nmCRPC): A comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study
| Autor: | Payne, H.A., Bulbul, M., Hatzimouratidis, K., Feyerabend, S., Kase, M., Manduley, A., McCaffrey, J., Procopio, G., Saad, M., Santoni, M., Sayers, I., Schnöller, T.J., Shatkovskaya, O., Antoni, L., Diels, J., Lopez-Gitlitz, A., McCarthy, S., Mundle, S.D., Pissart, G., Bögemann, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S520-S520 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|